文献速递消化道肿瘤放疗

老年(≥65岁)食管癌患者放化疗:一项回顾性单中心分析

Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis.
PubMed 文献 · Radiat Oncol · 2022-11-17

本研究回顾性分析2013年1月至2017年10月67例≥65岁食管癌患者,接受新辅助或根治性放化疗,比较>70岁与≤70岁患者的毒性及生存。两组严重毒性无显著差异,总生存30个月、无进展生存16个月,三模式治疗显著延长生存。结论认为老年患者放化疗可行有效,年龄本身不应作为治疗决策的唯一因素。

要点

  • ≥65岁食管癌患者放化疗的急性及晚期严重毒性在>70岁与≤70岁组间无显著差异。
  • 全组中位总生存30个月,中位无进展生存16个月。
  • 三模式治疗显著延长总生存和无进展生存,与年龄无关。

核心结论

  • ≥65岁食管癌患者放化疗可行且有效,急性和晚期毒性数值可与接受相同治疗的年轻(<65岁)食管癌患者队列相比。
  • 治疗开始时的年龄本身不应作为决定因素,功能状态、治疗相关并发症风险、预期寿命和患者偏好应纳入治疗选择。

研究设计与样本

  • 回顾性单中心分析,纳入2013年1月至2017年10月67例>65岁食管癌患者,其中34例(50.7%)>70岁。
  • 治疗为放疗联合卡铂/紫杉醇或氟尿嘧啶(5-FU)/顺铂化疗,意向为新辅助或根治性放化疗。
  • 67例均接受放化疗,44例(65.6%)为新辅助意向,23例(34.4%)为根治性意向;其中>70岁者分别为22例和12例(两治疗组中分别占50%和52.2%)。
  • 中位年龄71岁,体能状态良好(ECOG 0:57.6%,ECOG 1:27.3%),中位随访24个月。
  • 多数患者为晚期肿瘤(T3期:n=51,79.7%)和淋巴结转移(N1期:n=54,88.5%)。

主要发现

  • 严重(CTCAE 3-5级)毒性(急性和晚期)在≤70岁与>70岁两组间无显著差异。
  • 急性毒性:21%发生3级事件,4例(4%)发生4级事件,2例(3%)发生1次5级事件。
  • 放化疗后晚期毒性:1级13例(22%),2级2例(3%),3级2例(3%),4级4例(7%),5级1例(2%)。
  • 全组中位总生存30个月,中位无进展生存16个月。
  • 根治性意向的老年患者与年轻患者相比,总生存(32个月 vs 25个月;p=0.632)和无进展生存(16个月 vs 12个月;p=0.696)均无显著差异。

关键数值与推荐

  • 三模式治疗显著延长总生存和无进展生存(p=0.005;p=0.018),与年龄无关。
  • 严重毒性在≤70岁与>70岁组间无显著差异,急性3级事件占21%,4级4例(4%),5级2例(3%)。

临床怎么用

  • 作者认为,≥65岁食管癌患者放化疗可行且有效,急性和晚期毒性数值可与接受相同治疗的年轻(<65岁)患者队列相比。
  • 作者认为,治疗开始时的年龄本身不应作为决定因素,功能状态、治疗相关并发症风险、预期寿命和患者偏好应纳入治疗选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Present studies on the efficacy and safety of curative chemoradiation therapy (CRT) with esophageal cancer reflect heterogenous results especially in elderly patients. The aim of this study was to evaluate the toxicity and efficacy of CRT in patients ≥ 65 years. In a cohort, the focus centered around treatment-related toxicity (CTCAE Grade > 3), overall survival as well as progression free survival, comparing these rates in-between patients older than 70 years to those younger than 70 years. METHODS: A total of 67 patients older than 65 years (34 (50.7%) were older than 70 years) met the inclusion criteria for retrospective analysis (period from January 2013 to October 2017). Treatment consisted of radiotherapy and chemotherapy with carboplatin/paclitaxel or fluorouracil (5-FU)/cisplatin with the intention of neoadjuvant or definite chemoradiation. A sum of 67 patients received CRT (44 (65.6%) patients in neoadjuvant, 23 (34.4%) in definite intent). Of these, 22 and 12 patients were older than 70 years (50% and 52.2% in both treatment groups, respectively). Median age was 71 years and patients had a good physical performance status (ECOG 0: 57.6%, ECOG 1: 27.3%). Median follow-up was 24 months. Most patients had advanced tumour stages (T3 stage: n = 51, 79.7%) and nodal metastasis (N1 stage: n = 54, 88.5%). A subgroup comparison was conducted between patients aged ≤ 70 years and > 70 years. RESULTS: In severe (CTCAE Grade 3-5) toxicities (acute and late), no significant differences were observed between both patient groups (< 70 years vs. > 70 years). 21% had acute grade 3 events, 4 patients (4%) had grade 4 events, and two patients (3%) had one grade 5 event. Late toxicity after CRT was grade 1 in 13 patients (22%), grade 2 in two (3%), grade 3 in two (3%), grade 4 in four (7%), and grade 5 in one (2%). Median overall survival (OS) of all patients was 30 months and median progression-free survival (PFS) was 16 months. No significant differences were seen for OS (32 months vs. 25 months; p = 0.632) and PFS (16 months vs. 12 months; p = 0.696) between older patients treated with curative intent and younger ones. Trimodal therapy significantly prolonged both OS and PFS (p = 0.005; p = 0.018), regardless of age. CONCLUSION: CRT in elderly patients (≥ 65 years) with esophageal cancer is feasible and effective. Numbers for acute and late toxicities can be compared to cohorts of younger patients (< 65 years) with EC who received the same therapies. Age at treatment initiation alone should not be the determining factor. Instead, functional status, risk of treatment-related morbidities, life expectancy and patient´s preferences should factor into the choice of therapy.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Linde P, Mallmann M, Adams A, et al. Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis. Radiat Oncol. 2022. PMID: 36397163. doi:10.1186/s13014-022-02160-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。